Vuong, Lynda; Cornish, Andrew; Khandwala, Yash; Jiang, Hui; Mascareno, Eduardo; Zheng, Doris; Rappold, Phillip; Leibold, Josef; Sabio, Erich; Weiss, Kate; Gonzalez, Carlene; Rittenhouse, Nicole; Ji, Liangliang; Zhang, Jing; Adlesic, Mojca; Akin, Oguz; Flynn, Jessica; Krishna, Chirag; Sanchez, Alejandro; Natale, Renzo Di; Blum, Kyle; Russo, Paul; Coleman, Jonathan; Frew, Ian; Chowell, Diego; Chen, Yingbei; Solit, David; Ostrovnaya, Irina; Motzer, Robert; Voss, Martin; Kotecha, Ritesh; Chan, Timothy; Kuo, Fengshen; Li, Ming; Hakimi, A. Ari

Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma

分子异质性和免疫浸润驱动上尿路尿路上皮癌的临床结局

EUROPEAN UROLOGY

IF25.2

2025-03-011

OAAI

Kim, Kwanghee; Alam, Syed M.; Kuo, Fengshen; Chen, Ziyu; Yip, Wesley; Katims, Andrew B.; Chu, Carissa; Lenis, Andrew T.; Hu, Wenhuo; Ozcan, Gamze Gokturk; Chen, Jie-Fu; Firouzi, Sanaz; Elhanati, Yuval; Clinton, Timothy N.; Aulitzky, Andreas; Almassi, Nima; Fujii, Yoich; Tracey, Andrew T.; Reisz, Peter A.; Budhu, Sadna; Vuong, Lynda; Eichholz, Jordan; Woo, Hyung Jun; Nogueira, Lucas; Gao, Sizhi P.; Scherz, Avigdor; Aggen, David H.; Rosenberg, Jonathan E.; Pietzak, Eugene J.; Seshan, Venkatraman; Greenbaum, Benjamin; Becker, Anton; Akin, Oguz; Iyer, Gopa; Al-Ahmadie, Hikmat; Hakimi, A. Ari; Merghoub, Taha; Coleman, Jonathan A.

Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1

FRONTIERS IN IMMUNOLOGY

IF5.9

2023-08-289

OAAI

Tumor immune microenvironment determinants of response to lenvatinib and a PD-1 blockade in clear cell renal cell carcinoma

CANCER RESEARCH

IF16.6

2023-08-150

PRE

Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer

IMMUNITY

IF26.3

2022-11-0180

OAAI

Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity

NATURE GENETICS

IF31.8

2022-07-1141

Ma, Xiaoxiao; Riaz, Nadeem; Samstein, Robert M.; Lee, Mark; Makarov, Vladimir; Valero, Cristina; Chowell, Diego; Kuo, Fengshen; Hoen, Douglas; Fitzgerald, Conall W. R.; Jiang, Hui; Alektiar, Jonathan; Alban, Tyler J.; Juric, Ivan; Parthasarathy, Prerana Bangalore; Zhao, Yu; Sabio, Erich Y.; Verma, Richa; Srivastava, Raghvendra M.; Vuong, Lynda; Yang, Wei; Zhang, Xiao; Wang, Jingming; Chu, Lawrence K.; Wang, Stephen L.; Kelly, Daniel W.; Pei, Xin; Chen, Jiapeng; Yaeger, Rona; Zamarin, Dmitriy; Zehir, Ahmet; Gonen, Mithat; Morris, Luc G. T.; Chan, Timothy A.

A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma

CANCER DISCOVERY

IF33.3

2022-06-2713

Rappold, Phillip M.; Vuong, Lynda; Leibold, Josef; Chakiryan, Nicholas H.; Curry, Michael; Kuo, Fengshen; Sabio, Erich; Jiang, Hui; Nixon, Briana G.; Liu, Ming; Berglund, Anders E.; Silagy, Andrew W.; Mascareno, Eduardo A.; Golkaram, Mahdi; Marker, Mahtab; Reising, Albert; Savchenko, Alexander; Millholland, John; Chen, Ying-Bei; Russo, Paul; Coleman, Jonathan; Reznik, Ed; Manley, Brandon J.; Ostrovnaya, Irina; Makarov, Vladimir; DiNatale, Renzo G.; Blum, Kyle A.; Ma, Xiaoxiao; Chowell, Diego; Li, Ming O.; Solit, David B.; Lowe, Scott W.; Chan, Timothy A.; Motzer, Robert J.; Voss, Martin H.; Hakimi, A. Ari

Improved prediction of immune checkpoint blockade efficacy across multiple cancer types

改进了对多种癌症类型的免疫检查点阻断效果的预测

NATURE BIOTECHNOLOGY

IF41.7

2021-11-01142

Chowell, Diego; Yoo, Seong-Keun; Valero, Cristina; Pastore, Alessandro; Krishna, Chirag; Lee, Mark; Hoen, Douglas; Shi, Hongyu; Kelly, Daniel W.; Patel, Neal; Makarov, Vladimir; Ma, Xiaoxiao; Vuong, Lynda; Sabio, Erich Y.; Weiss, Kate; Kuo, Fengshen; Lenz, Tobias L.; Samstein, Robert M.; Riaz, Nadeem; Adusumilli, Prasad S.; Balachandran, Vinod P.; Plitas, George; Hakimi, A. Ari; Abdel-Wahab, Omar; Shoushtari, Alexander N.; Postow, Michael A.; Motzer, Robert J.; Ladanyi, Marc; Zehir, Ahmet; Berger, Michael F.; Gonen, Mithat; Morris, Luc G. T.; Weinhold, Nils; Chan, Timothy A.

High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab

MOLECULAR CANCER RESEARCH

IF4.7

2021-05-2623